




Report on Corporate Governance

Company's philosophy on corporate governance

Laurus Labs corporate governance framework establishes rigorous standards for stakeholder engagement, prioritizing long-term sustainable growth and value creation over short-term gains. Built upon the pillars of empowerment and accountability, our governance code guides every strategic action. As a responsible corporate citizen, we operate with total transparency to meet our societal commitments and deliver lasting impact.

We are committed to follow and practice our core values to advance **"Chemistry for Better Living"** to become a leading player in offering integrated solutions to global pharmaceutical needs in creating a healthier world. Following core values act like a compass, that keeps the organisation cruising in the right direction:



Laurus Labs is a research-driven pharmaceutical manufacturing organization, and has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since inception, the Company has also been developing and manufacturing Active Pharmaceutical Ingredients (APIs) and Intermediates. We scaled our pharmaceutical value chain by attaining a global leadership position in APIs, including anti-retroviral (ARV), oncology, cardiovascular, and gastro therapeutics. Our position was strengthened by our backward-integration capability while remaining highly regulatory compliant across all operations. We are committed to improve global health outcomes by manufacturing high-quality pharmaceuticals under a unified quality standard for all markets.

The Securities and Exchange Board of India ("SEBI") regulates corporate governance norms for listed companies in India through the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"). We are in compliance with the corporate governance norms, as prescribed under the SEBI Listing Regulations.

Board of Directors

Composition

The Board comprises optimal combination of Executive Directors and Non-Executive Independent Directors having knowledge and experience in the business and industry. The Company has a diverse, experienced, and

well-informed Board. The Board provides leadership, strategic guidance and independent views to the Company's management while discharging its fiduciary responsibilities, thereby ensuring that the management adheres to corporate governance standards of ethics, transparency and disclosure. The Board's responsibility includes exercising appropriate control to ensure that the Company is managed efficiently to fulfill stakeholders' aspirations, societal expectations and exercising independent judgment on the Company's performance and functioning. The Board acts in long term interests of the stakeholders without any conflict and make informed decisions and exercise due care and diligence in overseeing the management of the business of the Company.

The Company's Board represents an appropriate mix of Executive and Non-executive Independent Directors, which is in compliance with the requirements of the Companies Act, 2013 ("the Act") and the SEBI Listing Regulations and is also in line with the robust corporate governance practices. The Company's Board has a total strength of 10 (ten) Directors on the Board, comprising of 5 (five) Executive Directors and 5 (five) Non-executive Independent Directors. The Board has 2 (two) woman directors including one Independent Director. The Chairman of the Board is a Non-Executive Independent Director. The Chairman and the Chief Executive Officer (CEO) of the Company have their own separate roles as a measure of good corporate governance standards. The brief profiles of the Directors are placed on the Company's website <https://www.lauruslabs.com/our-people.html>.

In terms of the provisions of the Act, none of the Directors on the Board is holding office as a director in more than 20 (twenty) companies or more than 10 (ten) public companies. In terms of Regulation 17A of the SEBI Listing Regulations, none of the Directors of the Company is a director in more than 7 (seven) listed companies. Further, pursuant to Regulation 26(1) of the SEBI Listing Regulations, none of the Directors of the Company is a member of more than 10 (ten) committees or chairman of more than five committees across all the public companies in which they are Directors. The Directors have made necessary disclosures regarding committee positions in other public companies.

The Directors submit annual disclosure to the Company about the Board and Board Committee positions, he/

she occupies in other companies. They also inform the Company of any changes regarding their directorships and committee positions. In addition, the directors also submit annual affirmation of the Code of Conduct of the Company. The Independent Directors provides annual declaration of compliance of the criteria of independence as defined under the Act and the SEBI Listing Regulations. All Independent Directors are registered with the Independent Director's databank and requisite disclosures have been received from them in this regard. After assessment of such disclosures, declarations and confirmations, the Board is of the view that all the Independent Directors fulfil the conditions specified under the Act and the SEBI Listing Regulations and are independent of the management. The Board composition and other details as on March 31, 2026, are as hereunder:

Sl. No.	Name of the Director and DIN	Category of Directorship	Date of joining the Board	Whether present at the previous AGM held on June 26, 2025	No. of Directorship in listed entities including this listed entity (Regulation 17A of SEBI Listing Regulations)	Number of memberships/ chairmanship in Audit/ Stakeholders' Relationship Committee(s) including this listed entity (Regulation 26(1) of the SEBI Listing Regulations)	
						Chairman	Member ⁴
1	Dr. Ravindranath Kancharla ¹ DIN: 00117940	Non-Executive Chairman and Independent Director	18-05-2017	Yes	1	1	1
2	Dr. Satyanarayana Chava ¹ DIN: 00211921	Promoter, Executive Director and Chief Executive Officer	21-01-2006	Yes	1	0	0
3	Mr. V V Ravi Kumar ¹ DIN: 01424180	Promoter, Executive Director and Chief Financial Officer	30-11-2006	Yes	1	0	1
4	Dr. C V Lakshmana Rao ² DIN: 06885453	Promoter, Executive Director	08-03-2018	Yes	1	0	1
5	Mr. Krishna Chaitanya Chava ¹ DIN: 06831883	Promoter, Executive Director	25-04-2024	Yes	1	0	0
6	Mrs. Soumya Chava ¹ DIN: 06831892	Promoter, Executive Director	25-04-2024	Yes	1	0	0
7	Mrs. Aruna Bhinge ¹ DIN: 07474950	Non-Executive and Independent Director	07-07-2016	Yes	3	2	1
8	Dr. Rajesh Koshy Chandy ³ DIN: 07575240	Non-Executive and Independent Director	27-07-2016	No	1	0	1
9	Mr. Sekar Karnam ¹ DIN: 07400094	Non-Executive and Independent Director	25-04-2024	Yes	2	1	2
10	Mr. Ramesh Subrahmanian ³ DIN: 02933019	Non-Executive and Independent Director	25-07-2024	Yes	1	0	1

Notes:

¹Indian nationality

²Nationality of Australia

³Nationality of United States of America

⁴Membership include Chairperson position

Name of the listed entities where the person is a director and the category of directorship

Other than on the Board of the Company, which is a listed entity, the following Directors are holding directorships in other listed entities as shown below:

Mrs. Aruna Bhinge –

- Punjab Chemicals and Crop Protection Limited as an Independent Director;
- Mahindra EPC Irrigation Limited as an Independent Director

Mr. Sekar Karnam –

- Ugro Capital Limited as an Independent Director

Other than the above, our Directors do not hold directorship in any other listed company.

Disclosure of relationships between directors inter-se

Dr. Satyanarayana Chava is the father of Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava. Mr. Krishna Chaitanya Chava is the son of Dr. Satyanarayana Chava and Mrs. Soumya Chava is the daughter of Dr. Satyanarayana Chava. Other than these three directors, none of the directors are related to any other director.

Number of shares held by non-executive directors

Dr. Ravindranath Kancharla and Mrs. Aruna Bhinge are holding 8,75,000 and 17,500 equity shares, respectively, as on March 31, 2026.

Dr. Rajesh Koshy Chandy, Mr. Sekar Karnam and Mr. Ramesh Subrahmanian are not holding any shares or convertible instruments in the Company.

Details about familiarization programme

The Directors are updated with the latest developments affecting the Company and industry. Apart from regular presentations, updates on the Company's business strategies and associated risks, are presented to the Board. Regulatory updates are also presented to the Board in quarterly meetings. Each Director has access to the Company's information and freedom to interact with the Senior Management.

To familiarise a new Independent Director with the Company, an induction kit containing documents about the Company is provided, which inter alia, includes Annual Reports, Investor Presentations, recent Press Releases, Organisation Chart, Pharma Industry Primers, Code of Conduct and the Memorandum and Articles of Association and a brief on Company's Board practices. The visits of the new Independent Director to plants and research locations are organised to familiarise with the Company's business and operations.

Further, the senior leadership periodically makes presentations to the Board members on the operations

of the Company, its plans, strategy, risks involved, new initiatives etc. and seek their views and suggestions on the same. Further, the Board members have been provided with various Company policies, including the Code of Conduct for Directors and Senior Management.

The details of the familiarization programs have been placed on the Company's website at:

https://www.lauruslabs.com/Investors/PDF/Disclosures/Familiarisation_programme_FY2026.pdf

Core skills/ expertise/ competencies identified by the Board as required in the context of its business(es) and sector(s) for an efficient functioning and those available with the Board

- Hands on pharma industry experience in sourcing, manufacturing, marketing and business development.
- Accounting, financial, budget and costing expertise.
- Legal and HR expertise.
- Experience in quality.
- Expertise in corporate governance.
- Formulation of effective strategy.
- Experience in supply chain management, generics.

The Board members possess the following core skills / expertise / competencies

Dr. Ravindranath Kancharla – a, e and f of above

Dr. Satyanarayana Chava – a, b, c, d, e, f and g of above

Mr. V V Ravi Kumar – a, b, c, e and f of above

Dr. C V Lakshmana Rao – a, d, e and f of above

Mr. Krishna Chaitanya Chava – a, e, f and g of above

Mrs. Soumya Chava – a, e, f and g of above

Dr. Rajesh Koshy Chandy – a, b, e and f of above

Mrs. Aruna Bhinge – a, b, c, e and f of above

Mr. Sekar Karnam – b, e and f of above

Mr. Ramesh Subrahmanian – a, b, e and f of above

Separate meeting of Independent Directors

In terms of Schedule IV of the Act and Regulation 25 of the SEBI Listing Regulations, Independent Directors of the Company are required to hold at least one meeting in a financial year, without the attendance of non-Independent Directors and members of the Management. It is recommended that all the independent directors shall strive to be present at such meeting.

During the financial year 2025-26, a separate meeting of the Independent Directors was held on March 12, 2026 to review the performance of the Chairman, Non-Independent Directors, Board Committees, Board as a whole, and the quality and timeliness of flow of information



between the Company's management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

The Independent Directors have expressed satisfaction on the outcome of the review of performance of the Non-Independent Directors, Chairman, Board Committees and Board as a whole. The assessment on the quality and timeliness of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties were also found to be satisfactory.

Confirmation about Independent Directors

In the opinion of the board, the independent directors fulfil the conditions specified in the SEBI Listing Regulations and are independent of the management.

As required under the SEBI Listing Regulations, a certificate from Company Secretary in Practice that none of the directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/ Ministry of Corporate Affairs or any such statutory authority, is attached to this Report as **Annexure-A**.

Further, Annual Secretarial Compliance Report issued by M/s RPR & Associates, Company Secretaries, Secretarial Auditor of the Company, in terms of Regulation 24A of the SEBI Listing Regulations is also attached to this Report as **Annexure-B**.

Board evaluation

In terms of the provisions of the Act and the SEBI Listing Regulations, one of the key functions of the Board and the Nomination and Remuneration Committee ("NRC") is to monitor and undertake the Board evaluation on an annual basis. The NRC has laid down the evaluation criteria for review of the performance of the individual Directors, Chairman, Board Committees and the Board as a whole.

Evaluation criteria and process

For the financial 2025-26, Board evaluation was conducted internally based on the criteria identified by the NRC. The evaluation process was undertaken using the automated process. The methodology included circulation of questionnaires and receiving responses from the Board members. The summary findings/ recommendations were discussed. The Independent Directors at their separate meeting also reviewed the evaluation outcome of the performance of the Chairman, Non-Independent Directors, Board Committees, Board as a whole, and the quality and timeliness of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties. The evaluation process inter alia broadly covered the following parameters:

Board and Board Committees: ■ adequacy of the size and structure of the Board, Board diversity, and competencies of Board members and sufficiency of their expertise for Board effectiveness; ■ adequacy of review of strategic plan and annual Budgets; ■ adequacy of the number of Board/ Committee meetings held and timely receipt of notice and agenda for the meetings, and minutes of the proceedings are accurately recorded; ■ adequacy of the Board meetings conducted in a manner that encourages open communication and meaningful participation; ■ adequacy of the statutory committees constituted with well-defined scope and Committee decisions are conveyed to the Board; ■ adequacy of the flow of information between the Board and management exists on an ongoing basis; ■ adequacy of the time devoted by the Board on current and potential strategic issues; ■ adequacy of the Board undertaking review of the high-risk issues impacting the organization; ■ appropriateness and adequacy of the succession plan; ■ adequacy of the secretarial and logistical support available for conducting Board meetings; ■ appropriateness of the overall Board performance is suiting the requirements of business and is meeting Corporate Governance provisions of the statute; ■ appropriateness of the mandate, composition and working procedures of the Board Committees are clearly defined and disclosed; ■ appropriateness of the Board Committees fulfilling their functions as assigned by the Board and under the applicable laws; ■ adequacy of the independence of the Board Committees from the Board; ■ adequacy of the reporting by the Board Committees to the Board is sufficient; ■ adequacy of Board Committees' meetings are conducted in a manner that encourages open communication and meaningful participation of its members.

Individual Directors: ■ experience in the Pharma Industry; ■ knowledge about the Company and the sector in which it operates; ■ qualification and competencies for effective functioning of the Company and the Board; ■ understanding and fulfilling the functions as assigned by the Board or under the applicable laws; ■ ability to function as an effective team member; ■ taking initiative with respect to various areas; ■ regularity and punctuality in attending Board and Committee Meetings; ■ commitment to the Board and to the Company; ■ effective contribution to the Company and to the Board meetings; ■ demonstration of Integrity, including conflict of interest disclosures, maintenance of confidentiality, etc.; **Additional criteria for Independent Directors:** ■ whether independent from the Company and the other directors and there is no conflict of interest; ■ whether he/she exercises his/her own judgement and voices opinion freely. **Additional criteria for Chairman:** ■ effectiveness of leadership and ability to steer the meetings; ■ impartiality in conducting discussions, seeking views and dealing with dissent, etc.; ■ commitment to the Board and its meetings; ■ ability to keep shareholders' interest in mind during discussions and decisions

Outcome of Board evaluation

The Board expressed satisfaction with the outcome of the performance evaluation of the Chairman, Directors, Board Committees and Board as a whole. The assessment of the quality and timeliness of flow of information between the Company management and the Board, which is necessary for the Board to effectively and reasonably perform their duties were also found to be satisfactory.

Succession planning for the Board and senior management

The Company maintains an appropriate balance of knowledge, skills, diversity and experience in the Board and within the Company, in an endeavour to bring fresh perspectives while sustaining experience and continuity.

The succession planning of leadership positions is being done well in advance and the same is being reviewed from time to time. The leadership positions likely to be vacant due to retirement is being filled in advance to facilitate seamless transition of the role and responsibilities. Further, promoting existing employees to the leadership position within the organisation motivates the existing talent to earn future leadership roles.

Board strategy and budget meet

During the financial year 2025-26, the Board strategy and budget meeting was held on March 12, 2026 at the

Corporate Office in Hyderabad where the Board along with senior leadership management deliberated on various strategic matters.

The Board strategy meet facilitates the Board members to interact closely with the senior leadership of the various functions. Further, the strategy meet allows the Board members to get perspective and comprehensive update on various business strategic issues, opportunity to dedicate time for deeper strategic conversations.

Details of Directors who retire by rotation and are proposed for re-appointment at the AGM

Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava shall retire by rotation and being eligible, seek re-appointment. The details of the directors are as follows:

Mr. Krishna Chaitanya Chava

Mr. Krishna Chaitanya Chava brings over a decade of experience in strategic management, business development and project management. His leadership in the Synthesis division since 2017 has been instrumental in driving business diversification within CDMO Synthesis, transforming it into the top profit generator for the Company. His strategic insights and effective management practices have contributed to the division's ongoing success and its potential for future growth.

Directorship Details

Sl. No.	Name of the companies/ bodies corporate/ firms/ association of individuals	Nature of interest or concern/ change in interest or concern	Shareholding (No. of shares/ percentage)	Date on which interest or Concern arose/ changed
1	Laurus Labs Limited CIN: L24239AP2005PLC047518	Executive Director	20,699 (0.004%)	25-04-2024
2	Sriam Labs Private Limited CIN: U24239AP2002PTC121365	Director	Nil	25-07-2019
3	Chemiasoft Private Limited CIN: U72300TG2014PTC092281	Director	Nil	01-03-2014
4	Laurus Synthesis Private Limited CIN: U24110AP2020PTC121364	Director	Nil	18-05-2020
5	Laurus Specialty Chemicals Private Limited CIN: U24110TG2022PTC168791	Director	Nil	01-12-2022

Committee Membership Details

Sl. No.	Name of the Company	Name of the Committee	Chairman/ Member
1	Sriam Labs Private Limited CIN: U24239TG2002PTC038490	CSR Committee	Member
2	Laurus Labs Limited CIN: L24239AP2005PLC047518	Risk Management Committee	Member

Mrs. Soumya Chava

Mrs. Soumya Chava possesses a blend of skills in supply chain management and business development, particularly in the generics market. As the Head (Commercial) at Laurus Labs since August 2023, she has quickly established herself by implementing global procurement strategies and leading numerous commercial engagements. Additionally, she effectively manages the Company's CSR initiatives, showcasing her versatile leadership.

Directorship Details

Sl. No.	Name of the companies/ bodies corporate/ firms/ association of individuals	Nature of interest or concern/ change in interest or concern	Shareholding (No. of shares/ percentage)	Date on which interest or Concern arose/ changed
1	Laurus Labs Limited CIN: L24239AP2005PLC047518	Executive Director	22,940 Equity Shares (0.004%)	25-04-2024
2	Theia Jewellery Private Limited CIN: U52100TG2015PTC101259	Director	50,000 Equity Shares (50%)	19-10-2015
3	Laurus Synthesis Private Limited CIN: U24110AP2020PTC121364	Director	Nil	22-07-2021
4	Laurus Specialty Chemicals Private Limited CIN: U24110TG2022PTC168791	Director	Nil	19-10-2024
5	Laurus Generics Inc. (USA)	Director	Nil	19-01-2024
6	Laurus Generics SA Pty (South Africa)	Director	Nil	19-10-2024
7	Chemiasoft Private Limited CIN: U72300TG2014PTC092281	Member	32,825 Equity Shares (0.24%) & 33,65,000 Preference Shares (53.53% of Preference Shareholding)	06-09-2017

Committee Membership Details

Sl. No.	Name of the Company	Name of the Committee	Chairman/ Member
1	Laurus Synthesis Private Limited CIN: U24110AP2020PTC121364	CSR Committee	Member
2	Laurus Labs Limited CIN: L24239AP2005PLC047518	Risk Management Committee	Member
3	Laurus Labs Limited CIN: L24239AP2005PLC047518	CSR Committee	Member

Board meetings

The schedule of the Board and Board Committee meetings are planned and circulated approximately 12 months in advance. Agendas are circulated in advance with detailed notes and supporting documents. In terms of the Act and the SEBI Listing Regulations, the Board of Directors must meet at least four times a year, with a maximum gap of 120 days between two board meetings. The Board met 7 (seven) times during the financial year 2025-26. The gap between the Board meetings didn't exceed 120 days. The details of directors' attendance at the AGM and Board meetings are given below:

Sl. No.	Name of the Director	Present at the previous AGM	Board meeting dates						No. of meetings		% Attendance	
			April 24, 2025	May 15, 2025	July 25, 2025	August 21, 2025	October 23, 2025	January 23, 2026	March 12, 2026	Held during the tenure		Attended
1	Dr. Ravindranath Kancherla									7	7	100
2	Dr. Satyanarayana Chava									7	7	100
3	Mr. V V Ravi Kumar									7	7	100
4	Dr. C V Lakshmana Rao									7	7	100
5	Mr. Krishna Chaitanya Chava									7	6	86
6	Mrs. Soumya Chava									7	7	100
7	Mrs. Aruna Bhinge									7	7	100
8	Dr. Rajesh Koshy Chandy									7	7	100
9	Mr. Sekar Karnam									7	7	100
10	Mr. Ramesh Subrahmanian									7	7	100
% Attendance		-	90	100	100	100	100	100	100	-	-	98.6

Attended through video conference Attended physically Leave of absence

Committees of the Board

The Company has 5 (five) Board-level Committees. The composition of the Board committees, inducting/ appointing members/ chairperson and making changes therein are approved by the Board. The recommendations of the Committees are submitted to the Board for approval. During the year, all recommendations of the Committees were approved by the Board. The details of the Committees and its members are given below:

Board Committees		
Audit Committee	Nomination and Remuneration Committee	Stakeholders Relationship Committee
Mr. Sekar Karnam Independent Director – Chairperson	Mrs. Aruna Bhinge Independent Director – Chairperson	Dr. Ravindranath Kancherla Independent Director – Chairperson
Mrs. Aruna Bhinge Independent Director – Member	Dr. Ravindranath Kancherla Independent Director – Member	Mr. V V Ravi Kumar Executive Director & CFO – Member
Dr. Rajesh Koshy Chandy Independent Director – Member	Dr. Rajesh Koshy Chandy Independent Director – Member	Dr. C V Lakshmana Rao Executive Director – Member
Mr. Ramesh Subrahmanian Independent Director – Member	Mr. Ramesh Subrahmanian Independent Director – Member	
Risk Management Committee	Corporate Social Responsibility Committee	
Dr. Satyanarayana Chava Executive Director & CEO – Chairperson	Mr. V V Ravi Kumar Executive Director & CFO – Chairperson	
Dr. Rajesh Koshy Chandy Independent Director – Member	Mrs. Aruna Bhinge Independent Director – Member	
Mr. Ramesh Subrahmanian Independent Director – Member	Dr. C V Lakshmana Rao Executive Director – Member	
Mr. V V Ravi Kumar Executive Director & CFO – Member	Mrs. Soumya Chava Executive Director – Member	
Dr. C V Lakshmana Rao Executive Director – Member		
Mr. Krishna Chaitanya Chava Executive Director – Member		
Mrs. Soumya Chava Executive Director – Member		

Note: status as on March 31, 2026.

Audit Committee



Mr. Sekar Karnam
Independent Director,
Chairperson of the Committee

Members

Mrs. Aruna Bhinge, Independent Director
Dr. Rajesh Koshy Chandy, Independent Director
Mr. Ramesh Subrahmanian, Independent Director

The Audit Committee is constituted in terms of the requirements of the provisions of Regulation 18 of the SEBI Listing Regulations and Section 177 of the Act, and governed by its terms of reference which are in line with the regulatory requirements mandated under the Act and the SEBI Listing Regulations.

The management of the Company is responsible for the preparation of the standalone and consolidated financial statements/ results and the Company's internal financial controls. The Audit Committee reviews and recommends to the Board the financial statements/ results. The financial statements/ results are prepared in accordance

with the applicable provisions of the Act, the SEBI Listing Regulations, and the Indian Accounting Standards. The accounting policies are consistent, and the judgments and estimates are reasonable and prudent so as to give true and fair view of the state of affairs of the Company. The financial statements are prepared on a going concern basis and adequate internal financial controls are followed by the Company.

The Audit Committee reviews reports of the Internal Auditors, meets Statutory Auditors as and when required and discusses their findings, suggestions, observations and other related matters. The Board has also approved framework for effective communication between Statutory Auditors and Those Charged with Governance ("TCWG"). Meetings are being held between the TCWG and the Statutory Auditors. It also reviews major accounting policies followed by the Company. The terms of reference of the Audit Committee are as per the SEBI Listing Regulations and the Act. The primary functions of the Audit Committee are as hereunder:

- Oversight of the Company's financial reporting process and the disclosure of its financial information;
- Reviewing the annual financial statements and auditor's report thereon before submission to the Board for approval;
- Reviewing the quarterly financial statements before submission to the Board for approval;
- Approval or any subsequent modification of transactions of the Company with related parties;
- Scrutiny of inter-corporate loans and investments;
- Reviewing adequacy of the internal control systems;
- Evaluation of internal financial controls and risk management systems;
- Reviewing the Internal audit reports relating to internal control weaknesses;

- Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- Recommendation for appointment, remuneration and terms of appointment of auditors;
- Approval of payment to statutory auditors for any other services rendered by them;
- Reviewing the rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation, etc.;
- Reviewing the implementation of the Code of Conduct on Insider Trading;
- Reviewing the functioning of the whistle blower mechanism;
- Oversight of the compliance with legal and regulatory requirements.

As on March 31, 2026, the Audit Committee comprises of 4 (four) Independent Directors. The Chairperson of the Audit Committee is an Independent Director. There was no change in the composition of the Audit Committee during the financial year 2025-26. All members of the Audit Committee are financially literate and bring in expertise in the fields of finance, accounts, economics, strategy, governance and risk management. The Audit Committee composition complies with the requirements of the Act and the SEBI Listing Regulations. The Chairperson of the Audit Committee attended the AGM held in the year 2025. The Company Secretary acts as secretary to the Audit Committee.

In terms of the Act and the SEBI Listing Regulations, the Audit Committee is required to meet at least four times in a financial year, with a maximum gap of 120 days between two meetings. The Audit Committee met 6 (six) times during the year, the details of the meetings held and attendance therein are given below. The maximum gap between any two meetings didn't exceed 120 days.

Sl. No.	Name of the Audit Committee member	Board meeting dates						No. of meetings		% Attendance
		April 24, 2025	July 25, 2025	August 21, 2025	October 23, 2025	January 23, 2026	January 28, 2026	Held during tenure	Attended	
1	Mr. Sekar Karnam Independent Director							6	6	100
2	Mrs. Aruna Bhinge Independent Director							6	6	100
3	Dr. Rajesh Koshy Chandy Independent Director							6	6	100
4	Mr. Ramesh Subrahmanian Independent Director							6	6	100
% Attendance		100	100	100	100	100	100	-	-	100

Attended through video conference Attended physically

Nomination and Remuneration Committee



Mrs. Aruna Bhinge
Independent Director,
Chairperson of the Committee

Members

Dr. Ravindranath Kancherla, Independent Director
Dr. Rajesh Koshy Chandy, Independent Director
Mr. Ramesh Subrahmanian, Independent Director

The Nomination and Remuneration Committee ("NRC") is constituted in terms of the requirements of the provisions of Regulation 19 of the SEBI Listing Regulations and Section 178 of the Act, and governed by its terms of reference which are in line with the regulatory requirements mandated under the Act and the SEBI Listing Regulations.

The role, function and terms of reference of the NRC are as prescribed under the SEBI Listing Regulations and the Act. NRC determines the Company's policy on all elements of the remuneration packages of the executive directors. The NRC has reviewed and evaluated the performance evaluation criteria for Board, its Committees and Directors including Independent Directors as per SEBI Circular dated January 5, 2017. The primary functions of the NRC are as hereunder:

- Review the composition, structure and size of the Board and recommend changes, if any (including the skills, knowledge, experience and diversity);
- Identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, recommend to the Board their appointment and removal;
- For appointment of an independent director, evaluate the balance of skills, knowledge and experience on the

Board and on the basis of such evaluation, formulate a description of the role and capabilities required of an independent director;

- Formulate the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration for the directors, key managerial personnel and other employees;
- Devising a policy on diversity of Board of Directors;
- Formulate criteria for performance evaluation;
- Oversee administration and implementation of the ESOP Scheme.

As on March 31, 2026, the NRC comprises of 4 (four) Independent Directors. The Chairperson of the NRC is an Independent Director. There was no change in the composition of the NRC during the financial year 2025-26. The NRC composition complies with the requirements of the Act and the SEBI Listing Regulations. The Chairperson of the NRC attended the AGM held in the year 2025. The Company Secretary acts as secretary to the NRC.

In terms of the SEBI Listing Regulations, the NRC is required to meet at least once in a financial year. The NRC met 4 (four) times during the year, the details of the meetings held and attendance therein are given below.

Sl. No.	Name of the NRC member	NRC meeting dates				No. of meetings		% Attendance
		April 23, 2025	October 23, 2025	January 23, 2026	March 10, 2026	Held during tenure	Attended	
1	Mrs. Aruna Bhinge Independent Director					4	4	100
2	Dr. Ravindranath Kancherla Independent Director					4	4	100
3	Dr. Rajesh Koshy Chandy Independent Director					4	4	100
4	Mr. Ramesh Subrahmanian Independent Director					4	4	100
% Attendance		100	100	100	100	-	-	100

Attended through video conference Attended physically

Stakeholders Relationship Committee



Dr. Ravindranath Kancherla
Independent Director,
Chairperson of the Committee

Members

Mr. V V Ravi Kumar, Executive Director & CFO
Dr. C V Lakshmana Rao, Executive Director

The Stakeholders' Relationship Committee ("SRC") is constituted in terms of the requirements with the provisions of Regulation 20 of the SEBI Listing Regulations and Section 178 of the Act and governed by its terms of reference which are in line with the regulatory requirements mandated by the Act and the SEBI Listing Regulations.




The role, function and terms of reference of the SRC are as prescribed under the SEBI Listing Regulations and the Act. The primary functions of the SRC are as hereunder:

- Reviewing resolution of the grievances of the security holders of the Company including complaints related to transfer/ transmission of shares, non-receipt of annual reports, non-receipt of dividends, issue of new/ duplicate share certificates, general meetings, etc.;
- Reviewing any investor grievances received through SEBI, BSE, NSE or SCORES and ensure its timely and speedy resolution;
- Reviewing the adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar and Share Transfer Agent ("RTA");

- Reviewing the measures taken for effective exercise of voting rights by shareholders;
- Reviewing the various measures and initiatives taken by the Company for reducing the quantum of unclaimed/ unpaid dividends;
- Reviewing compliance relating to all securities including dividend payments, transfer of unclaimed amounts or shares to the Investor Education and Protection Fund.

As on March 31, 2026, the SRC comprises of 3 (three) Directors, out of which one is Independent Director and 2 (two) are Executive Directors. The Chairperson of the SRC is an Independent Director. There was no change in the composition of the SRC during the financial year 2025-26. The SRC composition complies with the requirements of the Act and the SEBI Listing Regulations. The Chairperson of the SRC attended the AGM held in the year 2025. The Company Secretary acts as secretary to the SRC.

In terms of the SEBI Listing Regulations, the SRC is required to meet at least once in a financial year. The SRC met once during the year, the details of the meeting held and attendance therein is given below.

Sl. No.	Name of the SRC member	SRC meeting date		No. of meetings		% Attendance
		April 23, 2025	Held during tenure	Attended		
1	Dr. Ravindranath Kancherla Independent Director		1	1	100	
2	Mr. V V Ravi Kumar Executive Director & CFO		1	1	100	
3	Dr. C V Lakshmana Rao Executive Director		1	1	100	
% Attendance		100	-	-	100	

 Attended through video conference  Attended physically

The Company has received 7 complaints during the year 2025-26; resolved 7 complaints and no complaints were pending as on March 31, 2026. Further, during the year, there were no complaints which was not resolved to the satisfaction of shareholders.

Name and address of Compliance Officer

CS G Venkateswar Reddy
Vice President – Legal, Company Secretary and Compliance Officer
Laurus Labs Limited
Corp. Office: Plot No.103, Road No.1,
Jubilee Hills, Hyderabad - 500 033,
Telangana, India
CIN: L24239AP2005PLC047518
Email: secretarial@lauruslabs.com
Tel: +91 40-6659 4333/ 4320.

Corporate Social Responsibility Committee



Mr. V V Ravi Kumar
Executive Director & CFO,
Chairperson of the Committee

Members

Mrs. Aruna Bhinge, Independent Director
Mrs. Soumya Chava, Executive Director
Dr. C V Lakshmana Rao, Executive Director

The Corporate Social Responsibility ("CSR") Committee is constituted in terms of the requirements with the provisions of Section 135 of the Act read with rules made thereunder and governed by its terms of reference which are in line with the regulatory requirements mandated under the Act.

The role, function and terms of reference of the CSR Committee are as prescribed under the Act. The primary functions of the CSR Committee are as hereunder:

- Reviewing and recommending CSR Policy which shall indicate the activities to be undertaken by the Company in areas or subject, specified in Schedule VII of the Act;
- Monitoring the CSR Policy of the Company from time to time;
- Recommending the amount of expenditure to be incurred on the CSR activities;
- Reviewing and recommending the Annual Action plan for CSR Programs, including the budgets thereof,

their manner of execution, implementation schedules, modalities of utilisation of funds, and monitoring & reporting mechanism of the CSR Programs and any alteration, modification or amendment to the Annual Action Plan;

- Reviewing the impact assessment reports undertaken through independent agencies;
- Reviewing and recommending the Annual Report on CSR activities;
- Recommending any CSR project or program for categorising as Ongoing Project, which was initially not approved as a multi-year project and monitoring thereof.

As on March 31, 2026, the CSR Committee comprises of 4 (four) Directors, out of which one is Independent Director and 3 (three) are Executive Directors. The Chairperson of the CSR Committee is an Executive Director. There was no change in the composition of the CSR Committee during the financial year 2025-26. The CSR Committee composition complies with the requirements of the Act. The Company Secretary acts as secretary to the CSR Committee.

During the financial year, 2 (two) meetings of the CSR Committee were held, as detailed hereunder:

Sl. No.	Name of the CSR Committee member	CSR meeting dates		No. of meetings		% Attendance
		April 23, 2025	October 22, 2025	Held during tenure	Attended	
1	Mr. V V Ravi Kumar Executive Director & CFO			2	2	100
2	Mrs. Aruna Bhinge Independent Director			2	2	100
3	Dr. C V Lakshmana Rao Executive Director			2	2	100
4	Mrs. Soumya Chava Executive Director			2	2	100
% Attendance		100	100	-	-	100

 Attended through video conference  Attended physically

Risk Management Committee



Dr. Satyanarayana Chava
Executive Director & CEO,
Chairperson of the Committee

Members

- Dr. Rajesh Koshy Chandy, Independent Director
- Mr. Ramesh Subrahmanian, Independent Director
- Mr. V V Ravi Kumar, Executive Director & CFO
- Mr. Krishna Chaitanya Chava, Executive Director
- Mrs. Soumya Chava, Executive Director
- Dr. C V Lakshmana Rao, Executive Director

The Risk Management Committee ("RMC") is constituted in terms of the requirements with the provisions of Regulation 21 of the SEBI Listing Regulations, and governed by its terms of reference which are in line with the regulatory requirements mandated under the SEBI Listing Regulations.

The role, function and terms of reference of the RMC are as prescribed under the SEBI Listing Regulations. The primary functions of the RMC are as hereunder:

- Formulating a detailed Risk Management Policy which shall include:
 - A framework for identification of internal and external risks specifically faced by the Company, including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber security risks, compliance/legal risk, disaster risk or any other risk as may be determined by the Committee;
 - Measures for risk mitigation including systems and processes for internal control of identified risks
 - Business continuity plan
- Ensuring appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;

- Monitoring and overseeing implementation of the risk management policy, including evaluating the adequacy of risk management systems;
- Reviewing periodically the risk management policy, including by considering the changing industry dynamics and evolving complexity.

As on March 31, 2026, the RMC comprises of 7 (seven) Directors, out of which (2) two are Independent Directors and 5 (five) are Executive Directors. The Chairperson of the RMC is an Executive Director. There was no change in the composition of the RMC during the financial year 2025-26. The RMC composition complies with the requirements of the SEBI Listing Regulations. The Company Secretary acts as secretary to the RMC.

In terms of the SEBI Listing Regulations, the RMC is required to meet at least twice in a financial year and meetings of the RMC shall be conducted in such a manner that on a continuous basis not more than 210 days shall elapse between any two consecutive RMC meetings. The RMC met twice during the financial year, the details of the meeting held and attendance therein is given below. The gap between two meetings didn't exceed 210 days.

Sl. No.	Name of the RMC member	RMC meeting dates		No. of meetings		% Attendance
		July 21, 2025	January 30, 2026	Held during tenure	Attended	
1	Dr. Satyanarayana Chava Executive Director & CEO			2	2	100
2	Mr. V.V. Ravi Kumar Executive Director & CFO			2	2	100
3	Dr. C.V. Lakshmana Rao Executive Director			2	2	100
4	Mr. Krishna Chaitanya Chava Executive Director			2	1	50
5	Mrs. Soumya Chava Executive Director			2	2	100
6	Dr. Rajesh Koshy Chandy Independent Director			2	2	100
7	Mr. Ramesh Subrahmanian Independent Director			2	2	100
% Attendance		100	100	-	-	92.9

Attended through video conference Attended physically Leave of absence

Senior Management

The details of Senior Management Personnel of the Company are as hereunder:

- Dr. V Uma Maheswer Rao, President – Chemical R&D
- Mr. Srinivasa Rao S, President – Manufacturing and Operations
- Dr. Suresh Poda, President – Cell and Gene Therapy & Antibody Drug Conjugates
- Mr. Rajaram Iyer, Executive Vice President – Portfolio Management
- Mr. Ch. Sita Ramaiah, Executive Vice President – Finance
- Mr. Narasimha Rao Chava, Executive Vice President – Human Resources

- Mr. N. Babchand, Senior Vice President – Generics
- Mr. Sumeet Sobti, Senior Vice President – Supply Chain Management
- Dr. Thilek Kumar Muniyappan, Senior Vice President – Formulations-R&D
- Dr. Parkash Som, Senior Vice President – Regulatory Affairs
- Mr. Giridhar M, Senior Vice President – Quality Assurance
- Mr. G Venkateswar Reddy, Vice President – Legal & Secretarial & Compliance Officer

There was no change in the list of Senior Management Personnel of the Company during the financial year 2025-26.

Remuneration to Directors

Details of remuneration paid to Directors during the financial year 2025-26 are as follows:

a. Executive Directors

The remuneration paid to the Executive Directors during the financial year 2025-26 is as hereunder:

₹ in Crore						
Sl. No	Name of the Executive Director	Salary	Bonus	Perks	Others	Total
1	Dr. Satyanarayana Chava	14.46	10.08	0.25	0.01	24.80
2	Mr. V V Ravi Kumar	4.80	1.68	0.00	0.12	6.60
3	Dr. C V Lakshmana Rao	3.19	1.12	0.17	0.08	4.56
4	Mr. Krishna Chaitanya Chava	1.73	0.31	0.11	0.05	2.20
5	Mrs. Soumya Chava	1.11	0.20	0.00	0.04	1.35

Note: Rounding off. Service contracts, severance fee: nil; Notice period: 3 months; Stock options: Executive Directors are not entitled for any stock options.

b. Non-Executive Independent Directors

The remuneration paid to each Non-Executive Independent Director is in terms of approval given by the shareholders, as determined by the Board from time to time. During the financial year 2025-26, the Independent Directors were paid remuneration by way commission @₹ 20 lakhs per annum. Further, Independent Directors were also paid sitting fee @₹ 50,000/- for attending each meeting of the Board of Directors and each meeting of the Board Committees, the details of which are provided below:

₹ in Crore			
Sl. No	Name of the Non-Executive Independent Director	Commission	Total
1	Dr. Ravindranath Kancherla	0.20	0.06
2	Mrs. Aruna Bhinge	0.20	0.10
3	Dr. Rajesh Koshy Chandy	0.36 ¹	0.10
4	Mr. Sekar Karnam	0.20	0.07
5	Mr. Ramesh Subrahmanian	0.20	0.10

Note: Service contracts, severance fee: nil; Notice period: nil; Stock options: Non-Executive Independent Directors are not entitled for any stock options.

¹Difference due to payment in foreign exchange. Dr. Chandy is entitled to receive and paid commission of USD 40,000 per annum.

Nomination/ Remuneration Policy

The compensation of the Executive Directors comprises of fixed component, perquisites and performance-based incentive and is determined based on the remuneration prevailing in the industry and the performance of the Company. The remuneration package of the Executive Directors is periodically reviewed and suitable revision is recommended to the Board by the Nomination and Remuneration Committee. The Board shall recommend the same for the approval of the Shareholders.

The Nomination and Remuneration Policy as adopted by the Board is placed on the Company's website at: https://www.lauruslabs.com/Investors/PDF/Policies/Remuneration_Policy.pdf

Shareholder's Information

Annual General Meetings ("AGM")

Venue, date and time of the last 3 (three) Annual General Meetings:

Financial year	Date and time	Venue	Details of special resolutions passed
2022-23	July 14, 2023, 03:00 p.m.	Meeting conducted through Video Conference (VC)/ Other Audio-Visual Means (OAVM)	Nil
2023-24	July 11, 2024, 03:00 p.m.	Meeting conducted through Video Conference (VC)/ Other Audio-Visual Means (OAVM)	<ol style="list-style-type: none"> 1. Appointment of Mr. Krishna Chaitanya Chava (DIN: 06831883) as an Executive Director of the Company. 2. Appointment of Mrs. Soumya Chava (DIN: 06831892) as an Executive Director of the Company. 3. Appointment of Mr. Sekar Karnam as an Independent Director for a period of 5 years
2024-25	June 26, 2025, 03:00 p.m.	Meeting conducted through Video Conference (VC)/ Other Audio-Visual Means (OAVM)	<ol style="list-style-type: none"> 1. Approval of re-appointment of Dr. Satyanarayana Chava (DIN: 00211921) as an Executive Director & CEO of the Company. 2. Approval of re-appointment of Mr. V V Ravi Kumar (DIN: 01424180) as an Executive Director & CFO of the Company. 3. Approval of modification of terms of employment contract of Dr. C V Lakshmana Rao (DIN: 06885453), Executive Director of the Company. 4. Approval of modification of terms of employment contract of Mr. Krishna Chaitanya Chava (DIN: 06831883), Executive Director of the Company. 5. Approval of modification of terms of employment contract of Mrs. Soumya Chava (DIN: 06831892), Executive Director of the Company.

No special resolution has been passed through postal ballot during the financial year 2025-26. Therefore, no one has been appointed for conducting the postal ballot exercise. There is no proposal for passing any special resolution through the postal ballot, and therefore, details for providing procedure for postal ballot is not applicable.

Means of Communication

a. **Quarterly and annual results:** Quarterly and annual results of the Company are published in widely circulated national newspapers such as the Business Standard (English) and the local vernacular language newspaper Prajasakthi (Telugu). The results and official news releases, presentations made to the institutional investors/ analysts are also displayed on the Company's website, www.lauruslabs.com. The financial results were sent, if asked for, to the registered e-mail IDs of members.

b. **Annual Report:** The Company's Annual Report containing, inter alia, the Board's Report along with annexures, Corporate Governance Report, Business Responsibility and Sustainability Report, Management's Discussion and Analysis (MDA), Audited Standalone and Consolidated Financial Statements together with Auditors' Report, Notice of AGM and other important information are circulated to the members and others so entitled. The Annual Report is also available on the Company's website, www.lauruslabs.com.

Annual Reports were sent to the Members through e-mail, in terms of the directions given in the circulars issued by Ministry of Corporate Affairs ("MCA") and the Securities and Exchange Board of India ("SEBI"). However, the Company has provided hard copy of Annual Report to those shareholders who request for the same.

c. **Earning calls:** Earnings calls with analysts and investors and their transcripts and audio recordings are also posted on the website. The investor presentations made to institutional investors or to the analysts are also available in our website, www.lauruslabs.com.

d. **News releases, presentations, etc.:** The Company has robust process to disseminate relevant information to its stakeholders, including members, analysts, customers, business partners, employees and the society at large. Further, all material information which has impact on the operations of the Company is sent to the Stock Exchanges and also the same is placed on the Company's website. Details of communications made during the year are as hereunder:

Means of communication	Number
Publication of results	4
Results earnings calls	4
Press releases/ intimations/ other disclosures and filings	80

e. **Website:** The Company's website, www.lauruslabs.com, is the primary source of information regarding the Company, its facilities and operations, where all official news releases and presentations made to institutional investors and analysts are posted.

It also contains a separate dedicated investors section, as required under Regulation 46(2) of the SEBI Listing Regulations, where the information for members are available.

The Financial Results, official news releases, presentations made to the institutional investors/ analysts are also displayed on the Company's website, www.lauruslabs.com.

f. **Remindert to investors:** The Company send reminders to the shareholders for claiming their unclaimed/unpaid dividend on shares periodically.

g. **Disclosure with stock exchanges:** National Stock Exchange of India Ltd (NSE) and BSE Limited (BSE) maintain separate online portals, namely, NEAPS and Listing Centre, respectively, for electronic submission of information by listed companies. Various communications such as notices, press releases and the regular quarterly, half-yearly and annual compliances and disclosures are filed electronically on these portals.

h. **Designated exclusive e-mail ID:** The Company has a designated an e-mail ID exclusively for investor services: secretarial@lauruslabs.com.

Management Discussion and Analysis Report

The Management Discussion and Analysis Report forms part of this Report and is provided separately in this Integrated Report.

General Shareholder Information

a. Annual General meeting

AGM day, date and time	Thursday, July 2, 2026, at 3:00 p.m. IST
Venue	In accordance with the General Circular No. 3/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (MCA), the 21 st AGM of the Company will be held through VC/OAVM mode. The deemed venue for the same shall be at the Registered Office of the Company. More details have been given in the Notice of 21 st AGM.
Receipt of proxy forms	In terms of the relaxations granted by MCA, the facility for appointment of proxies by Members will not be available at the ensuing AGM as the same will be held through VC/ OAVM mode.
Remote e-voting dates	Cut-off date for remote e-voting: Thursday, June 25, 2026 Remote e-voting: Monday, June 29, 2026 at 9:00 a.m. IST to Wednesday, July 1, 2026 at 5:00 p.m. IST
Listing on Stock Exchanges (Equity)	The Company's equity shares are listed on the following Stock Exchanges: <ul style="list-style-type: none"> • National Stock Exchange of India Limited - Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 • BSE Limited - Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Annual Listing fees has been paid by the Company to the above stock exchanges
Stock Code	BSE Limited: 540222 NSE: LAURUSLABS
International Securities Identification Number (ISIN)	ISIN for the Company's Equity Shares is INE947Q01028
Depositories for Equity Shares	<ul style="list-style-type: none"> • National Securities Depository Limited (NSDL) • Central Depository Services (India) Limited (CDSL)

Description of voting rights	The equity shares issued by the Company carry equal voting rights.
Registrar and Transfer Agent (RTA) for equity shares	KFin Technologies Limited Selenium Building, Tower B, Plot No. 31-32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana - 500032. Tel: +91 40 6716 2222; Toll Free No.: 1-800-3454-001 Fax: +91 040-23001153 Email: einward.ris@kfintech.com Website: https://www.kfintech.com

b. Financial year

From April 1, 2025 to March 31, 2026 (i.e., from 1st April every year to 31st March of subsequent year).

c. There was no suspension of trading of securities of the Company during the year under review.

d. Dividend

For the financial year 2025-26, the Board has declared first interim dividend @ 40%, i.e., ₹ 0.80/- per equity share of the face value of ₹ 2/- each) on October 23, 2025 and second interim dividend @60%, i.e., ₹ 1.20/- per equity share on April 30, 2026. The record date for payment of 2nd interim dividend is May 8, 2026 and the payment will be made on May 20, 2026.

e. Unclaimed dividend

Pursuant to the provisions of Section 124 of the Act, dividend which remains unpaid or unclaimed for a period of seven years from the date of its transfer to unpaid dividend account, is required to be transferred by Company to the Investor Education and Protection Fund (IEPF), established by the Central Government under the provisions of Section 125 of the Act. Shareholders of the Company who have either not received or have not encashed their dividend warrants, for the financial years 2018-19, 2019-20, 2020-21, 2021-22, 2022-23, 2023-24, 2024-25 and 2025-26 are requested to claim their unpaid/ unclaimed dividend from the Company before transfer to the fund and further requested to submit the bank account details and email ID for recording in the RTA/Depository Participants systems for rendering better services to the shareholders. The details unclaimed/ unpaid dividends and their due date for transfer to IEPF is given below:

Dividend account	Type of dividend	Dividend per share (₹)	Date of declaration	Due date of transfer to IEPF (transfer to be done within 30 days from due date)	Amount outstanding as on March 31, 2026 (net) (₹)
2018-19	Final	1.50	July 11, 2019	August 17, 2026	71,861
2019-20	Interim	1.50	March 12, 2020	April 18, 2027	96,461
2019-20	Final	1.00	July 9, 2020	August 15, 2027	78,831
2020-21	1 st Interim	0.80	October 29, 2020	December 5, 2027	4,88,692
2020-21	2 nd Interim	0.40	January 28, 2021	March 5, 2028	2,36,657
2020-21	3 rd Interim	0.80	April 29, 2021	June 5, 2028	3,05,941
2021-22	1 st Interim	0.80	October 28, 2021	December 4, 2028	2,89,739
2021-22	2 nd Interim	1.20	April 28, 2022	June 4, 2029	3,31,884
2022-23	1 st Interim	0.80	October 21, 2022	November 27, 2029	2,06,685
2022-23	2 nd Interim	1.20	April 27, 2023	June 3, 2030	3,51,332
2023-24	1 st Interim	0.40	October 20, 2023	November 26, 2030	1,01,686
2023-24	2 nd Interim	0.40	April 25, 2024	June 1, 2031	1,07,419
2024-25	1 st Interim	0.40	October 24, 2024	Nov 30, 2031	59,203
2024-25	2 nd Interim	0.80	April 24, 2025	May 31, 2032	2,35,166
2025-26	1 st Interim	0.80	October 23, 2025	November 29, 2032	1,24,127
2025-26	2 nd Interim	1.20	April 30, 2026	June 6, 2033	Not applicable

In order to educate the shareholders and with an intent to protect their rights, the Company also sends reminders to shareholders to claim their unclaimed dividends/ shares before it is transferred to the IEPF. Shareholders may note that both the unclaimed dividends and corresponding shares once transferred to the IEPF, including all benefits accruing on such shares, if any, can be claimed from the IEPF following the procedure prescribed in the Rules. No claim shall lie in respect thereof with the Company.

f. Share transfer system

As on March 31, 2026, the total shares of the Company are in demat form only. As the Company's shares are currently traded in dematerialized form, the transfers are processed and approved in the electronic form by NSDL/ CDSL through their depository participants. The Company has appointed KFin Technologies Limited as its Registrars and Share Transfer Agent. The Company has signed a tripartite agreement with NSDL/CDSL and KFin Technologies Limited for availing dematerialization and other share related facilities.

The members may contact for the redressal of their grievances to either KFin Technologies Limited or the Company Secretary of the Company.

g. Distribution of Shareholding as on March 31, 2026

Category (No. of Shares)	No. of Shareholders	%	No. of Shares	%	
1	500	2,71,905	93.09	1,80,19,245	3.34
501	1000	8,892	3.05	66,58,776	1.23
1001	2000	4,916	1.68	71,42,438	1.32
2001	3000	1,863	0.64	46,30,875	0.86
3001	4000	880	0.30	30,99,709	0.57
4001	5000	618	0.21	28,49,664	0.53
5001	10000	1,303	0.45	93,98,435	1.74
10001 and above	1,707	0.58	48,80,57,440	90.41	
Total	2,92,084	100	53,98,56,582	100	

Note: Based on PAN.

h. Details of Shareholding in physical mode and electronic mode as on March 31, 2026

Sl. No.	Description	No. of shareholders	% of shareholders	No. of Shares	% of shareholding
1	Physical	0	NA	0	NA
2	NSDL	98,517	32.87	46,40,07,256	85.95
3	CDSL	2,01,224	67.13	7,58,49,326	14.05
Total		2,99,741	100	53,98,56,582	100

Note: Based on Folio.

i. Dematerialization of shares and liquidity

53,98,56,582 shares representing 100% shares have been in dematerialization form.

The Company has not issued any GDR/ADR and there are no outstanding warrants or any convertible instruments.

The Company has undertaken hedging activities for foreign exchange risk, whereas the Company has not undertaken any hedging for commodity price risk.

j. Location of Plants
Unit 1

Plot No 21, Jawaharlal Nehru Pharma City, Parawada Visakhapatnam 531021, Andhra Pradesh, India.

Unit 2

APSEZ, Unit-2, Plot No 19, 20 and 21, APSEZ Gurajapalem, Atchutapuram, Visakhapatnam 531011, Andhra Pradesh, India.

Unit 3

Plot No 18, Jawaharlal Nehru Pharma City, Parawada Visakhapatnam 531021, Andhra Pradesh, India.

Unit 4

Plot No 25, Lalamkoduru, Atchutapuram, Visakhapatnam 531011, Andhra Pradesh, India.

Unit 5

Plot No 102 and 103, SEZ, Lemarathi, Parawada, Visakhapatnam 531021, Andhra Pradesh, India.

Unit 6

Plot No 22 D and 22 E, APSEZ Denotified Area, Atchutapuram, Visakhapatnam 531011, Andhra Pradesh, India.

Unit 8

Plot No. 18B, APSEZ De-Notified Area, Moturupalem, Pudi and Gurajapalem Villages, Rambilli Mandal, Anakapalli - 531 011, Andhra Pradesh, India.

Unit 10

Plot No.18B, APSEZ De-Notified Area, Gurajapalem and Pudi Villages, Rambilli Mandal, Anakapalli - 531 011 Andhra Pradesh, India.

Research & Development Centre

Plot No.DS 1&2, IKP Knowledge Park, Turkapally, Shameerpet, Hyderabad - 500078, Telangana, India.

Address for correspondence:

Registered Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, 531021, Andhra Pradesh, India.

Corporate Office: Plot No. 103, Road No.1, Jubilee Hills, Hyderabad – 500033, Telangana, India.

More details are given in the Corporate Information page towards the end of this Integrated Report.

k. Disclosures pertaining to credit rating

Following are the Credit ratings obtained during the financial year, which are also available in the website of the Company i.e., <https://www.lauruslabs.com/investors.html>

Rating Agency	Facilities Rated	Amount Rated (₹ In Crores)	Rating Assigned	Date of Rating
CARE Ratings Limited	Long Term Bank Facilities	830.61 (Enhanced from 804.43 Cr)	CARE AA; Stable	July 01, 2025
CARE Ratings Limited	Long Term /Short Term Bank Facilities	1445.00 (Reduced from 1545Cr)	CARE AA; Stable/ CARE A1+	July 01, 2025
CARE Ratings Limited	Short Term Bank Facilities	1365.00 (Enhanced from 1,085.00)	CARE A1+	July 01, 2025

l. Other disclosures

Related party transactions

No transaction of material nature has been entered into by the Company with its Directors, Key Managerial Personnel and their relatives, that may have a potential conflict with the interest of the Company. The Register of Contracts containing transactions, in which Directors are interested, is placed before the Board regularly.

Transactions with Related Parties are disclosed in the Notes to the financial statements which forms part of the Integrated Report 2026.

In terms of the SEBI Listing Regulations, the Audit Committee and Board of Directors of the Company have adopted a policy on the related party transactions. The policy is placed on the Company's website at:

https://www.lauruslabs.com/Investors/PDF/Policies/Revised_RPT_Policy.pdf

Details of Non-compliances and penalties

BSE Limited and National Stock Exchange of India Limited had imposed a fine of ₹ 5,000/- per day on the Company for non-compliance of Regulation 17(1) of the SEBI Listing Regulations, pertaining to composition of Board of Directors of the Company which stipulates that 'not less than fifty percent of the board of directors shall comprise of non-executive directors', whereas our Company for a short period of time i.e., from May 18, 2024 till July 24, 2024 had five executive directors and four non-executive directors and on July 25, 2024, the Company had appointed another independent director on the Board and thereby complied with said Regulation.

Vigil mechanism/Whistle Blower Policy

The Board of Directors of the Company had adopted the Whistle Blower policy. The Company has established a mechanism for employees and Directors to report to the management, concerns about unethical

behaviour, actual or suspected fraud or violation of the Company's Code of conduct etc. The employees have been appropriately communicated within the organization about the mechanism and have been provided direct access to the Chairman of the Audit Committee. The mechanism also lays emphasis on making enquiry into whistle blower complaint received by the Company. The Audit Committee reviews periodically the functioning of the whistle blower mechanism. No employee has been denied access to the Audit Committee. A copy of the Whistle Blower Policy is hosted on the Company's website at: https://www.lauruslabs.com/Investors/PDF/Policies/Whistle_Blower_Policy_29-07-2021.pdf

Details of compliance with mandatory requirements and adoption of the non-mandatory requirements

The Company has complied with all the mandatory requirements of Corporate Governance as per the SEBI Listing Regulations, and is in the process of implementing the non-mandatory requirements.

Policy on material subsidiaries

In terms of the SEBI Listing Regulations, the Board of Directors of the Company has adopted a policy with regard to determination of material subsidiaries. The policy is placed on the Company's website at: <https://www.lauruslabs.com/Investors/PDF/Policies/PolicyOnMaterialityOfSubsidiaries.pdf>

Disclosures pertaining to commodity risk

The Company has framed a policy on Forex Risk Management for managing the risks faced and for hedging activities.

The risk management activities during the year, including their commodity hedging positions and the risks faced and managed. The Company has not undertaken any commodity hedging positions and therefore no risk exists. Necessary disclosure has been made in note no. 37 of the Standalone Financial Statement.

Details of utilization of funds raised through preferential allotment or qualified institutional placement
The Company has not raised any funds through preferential allotment or qualified institutional placement during the current financial year and hence not applicable.

The Board had accepted recommendations of various committees of the board which were mandatorily required in the relevant financial year.

Statutory Auditors fees

Total fees for all services paid by the Company and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part, for the financial year 2025-26 is as follows:

Particulars	₹ in Crores	
	2025-26	2024-25
Statutory Auditors	0.99	0.98
Limited Review	0.56	0.56
Others including fees for BRSR certification	0.53	0.36
Total	2.08	1.91

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

- a. number of complaints filed during the financial year – Nil
- b. number of complaints disposed of during the financial year - Nil
- c. number of complaints pending as on end of the financial year - Nil

Disclosures in relation to loans and advances in the nature of loans to firms/companies in which directors are interested

Sl. No	Name of company/ firm giving loans or advances	Amount (₹ in Crores)	Name and status of the company/ firm receiving loan/ advances	Name of the interested Director	Name and status of the company/ firm receiving loan/ advances
1	Laurus Labs Limited	475	Laurus Synthesis Private Limited ("LSPL")	Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava	Common Director, LSPL is Wholly-owned subsidiary of Laurus Labs Limited
2	Sriam Labs Private Limited ("Sriam")	28	LSPL	Mr. Krishna Chaitanya Chava	Common Director, both LSPL and Sriam are Wholly-owned subsidiaries of Laurus Labs Limited
3	Laurus Labs Limited	33	Laurus Bio Private Limited ("Laurus Bio")	Dr. Satyanarayana Chava, Mr. V V Ravi Kumar, Mrs. Aruna Bhinghe and Mr. Sekar Karnam	Common Director, Laurus Bio is subsidiary of Laurus Labs Limited

Material subsidiaries

The Company has no material subsidiaries, therefore, the requirement of providing details of the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries is not applicable.

Non-compliance of any requirements of corporate governance report of sub-paras (2) to (10) of Schedule V of the SEBI Listing Regulations

During the year, the Company has complied with the requirements of corporate governance report of sub-paras (2) to (10) of Schedule V of the SEBI Listing Regulations.

Adoption of discretionary requirements as specified in Part E of Schedule II of the SEBI Listing Regulations

The status of adoption of discretionary requirements are as hereunder:

- 1. **The Board:** The Chairman of the Board is Non-executive Independent Director and he has freedom to discharge his responsibilities from the Company's office as per his requirement in performance of his duties.
- 2. **Shareholders' rights:** The quarterly, half-yearly and annual results along with the investor presentation and press release are submitted to the stock exchanges, quarterly results are widely published in newspaper and also uploaded on the Company's website at www.lauruslabs.com.



3. **Audit qualifications:** The standalone and consolidated financial statements of the Company are unmodified.
4. **Separate post of Chairman and CEO:** The position of Chairman and CEO are held by different persons. Dr. Ravindranath Kancherla, Independent Director is the Chairman of the Board, and Dr. Satyanarayana Chava is the Executive Director and Chief Executive Officer of the Company. The Chairman is a Non-executive Director and not related to any other director or CEO of the Company.
5. **Reporting of internal audit:** The Internal Auditors of the Company submits their report at the quarterly meetings of the Audit Committee on internal audit findings.
6. **Independent Directors:** The independent directors meet once every year, without the presence of non-independent directors and members of the management.

The disclosures of the compliance with Corporate Governance requirements specified in Regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the SEBI Listing Regulations

Regulation	Particulars of Regulations	Compliance Status Yes/No
17	Board of Directors	Yes
18	Audit Committee	Yes
19	Nomination and Remuneration Committee	Yes
20	Stakeholders Relationship Committee	Yes
21	Risk Management Committee	Yes
22	Vigil Mechanism	Yes
23	Related party transactions	Yes
24	Corporate governance requirements with respect to subsidiary of listed entity	Yes
25	Obligations with respect to Independent Directors	Yes
26	Obligations with respect to Directors and Senior Management	Yes
27	Other corporate governance requirements	Yes
46(2)(b) to (i)	Functional website	Yes

Code of Conduct

In compliance with Regulation 26(3) of the SEBI Listing Regulations and the Act, the Company has framed and adopted a Code of Conduct policy. The Code is applicable to the members of the Board, the executive officers and all employees of the Company and its subsidiaries. The Code is available on our website at:

https://www.lauruslabs.com/Investors/PDF/Policies/Code_of_Conduct_Policy.pdf

All members of the Board, Key Managerial Personnel and Senior Management Personnel have affirmed compliance to the Code as on March 31, 2026.

Prevention of Insider Trading

The Company has adopted an Insider Trading policy to regulate, monitor and report trading by insiders under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This policy includes practices and procedures for fair disclosure of unpublished price-sensitive information, initial and continual disclosure. The Board reviews this policy on a need basis. The policy is available on our website at:

https://www.lauruslabs.com/Investors/PDF/Policies/Code_of_Prohibition_of_Insider_Trading.pdf

CEO and CFO Certification

As required by the SEBI Listing Regulations, the CEO and CFO certification is annexed in this Integrated Report as **Annexure-C**.

Auditors' Certificate on Corporate Governance

In terms of Schedule V of the SEBI Listing Regulations, the Certificate on Corporate Governance issued by Practising Company Secretary is annexed to this Integrated Report as **Annexure-D**.

Disclosures with respect to demat suspense account/ unclaimed suspense account

There are no shares which are lying in demat suspense account/ unclaimed suspense account as on March 31, 2026.

Disclosure of certain types of agreements binding listed entities

In terms of Regulation 30A of the SEBI Listing Regulations, there are no such agreements entered which will impact the management or control of the Company.

Declaration

I, Dr. Satyanarayana Chava, Executive Director and Chief Executive Officer, hereby declare that as provided under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, the Board Members and the Senior Management Personnel have confirmed compliance with the Code of Conduct for the financial year ended March 31, 2026.

For **Laurus Labs Limited**

Sd/-

Dr. Satyanarayana Chava

Executive Director and Chief Executive Officer

Place: Hyderabad

Date: April 30, 2026

Annexure – A to the Report on Corporate Governance

CERTIFICATE

(Pursuant to Regulation 34(3) read with Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To

The Members,

M/s. LAURUS LABS LIMITED

Laurus Enclave, Plot Office 01, E. Bonangi Village,

Parawada Mandal, Anakapalli District, Andhra Pradesh – 531021.

We have examined and verified the books, papers, minute books, forms and returns filed and other records maintained by M/s. Laurus Labs Limited (hereinafter referred to as the "Company") having its registered office at Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh – 531021 and the information provided by the Company and its directors and also based on the information available at the websites of Ministry of Corporate Affairs (i.e. www.mca.gov.in) and Securities and Exchange Board of India (i.e., www.sebi.gov.in), we hereby certify that as on the date of this certificate, none of the directors on the board of the Company have been debarred or disqualified from being appointed or continuing as directors of Company by Securities and Exchange Board of India / Ministry of Corporate Affairs or any such statutory authority during the year 2025-26.

For RPR & ASSOCIATES

Company Secretaries

Y Ravi Prasada Reddy

Proprietor

FCS No: 5783, C P No: 5360

Peer Review Certificate No. 1425/2021

UDIN: F005783H000244659

Place: Hyderabad

Date: April 30, 2026

Annexure – B to the Report on Corporate Governance

Annual Secretarial Compliance Report of M/s. Laurus Labs Limited for the year ended 31.03.2026

(Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments thereof)

We, M/s. RPR and Associates, Company Secretaries, Hyderabad, have examined:

(a) all the documents and records made available to us and explanation provided by M/s. Laurus Labs Limited (CIN: L24239AP2005PLC047518) having its registered office at Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh – 531021, (“the listed entity”);

(b) the filings/ submissions made by the listed entity to the stock exchanges;

(c) website of the listed entity; and

(d) any other document/ filing, as may be relevant, which has been relied upon to make this certification/report, for the year ended 31st March, 2026 (“Review Period”) in respect of compliance with the provisions of:

(a) the Securities and Exchange Board of India Act, 1992 (“SEBI Act”) and the Regulations, circulars, guidelines issued thereunder; and

(b) the Securities Contracts (Regulation) Act, 1956 (“SCRA”), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India (“SEBI”);

The specific Regulations, whose provisions and the circulars/guidelines issued thereunder, have been examined, include:

(a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;

(b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

(c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

(d) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018;

(e) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

(f) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; - No Buyback of securities during the review period.

(g) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; - Not Applicable during the review period.

(h) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Securities) Regulations, 2021; - Not Applicable during the review period.

(i) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013; - Not Applicable during the review period.

(j) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendments from time to time;

(k) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) (Amendment) Regulations, 2018 regarding the Companies Act and dealing with client;

and circulars/ guidelines issued thereunder and the additional affirmations as per the circulars issued by the stock exchanges on 16th March 2023 and subsequent amendments thereon; and based on the above examination, we hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:

Sl. No.	Compliance Requirement (Regulations/circulars/guidelines including specific clause)	Regulation/Circular No.	Deviations	Action Taken By	Type of Action	Details of Violation	Fine Amount (₹)	Management Response	Remarks
					Advisory /Clarification/Fine/ Show Cause Notice/ Warning, etc.				

No deviations / non-compliance during the review period

(b) The listed entity has taken the following actions to comply with the observations made in previous report of 2024-25;

Sl. No.	Compliance Requirement (Regulations/circulars/guidelines including specific clause)	Regulation/Circular No.	Deviations	Action Taken By	Type of Action	Details of Violation	Fine Amount	Observations/ Remarks of the Practicing Company Secretary	Management Response	Remarks
1	Composition of Board of Directors under SEBI (LODR)	17(1)(a)	The strength of Non-executive Directors in the Board was not at least 50% between 18 th May 2024 to 24 th July 2024	BSE and NSE	Fine	The strength of Non-executive Directors was not at least 50%	₹ 3,35,000/- to each Stock Exchange	The Company has paid the penalty amount and also complied with 17(1)(a) w.e.f 25/07/2024	Informed the Board and complied	Nil

We hereby report that, during the review period the compliance status of the listed entity with the following requirements:

Sr. No.	Particulars	Compliance status (Yes/No/NA)	Observations/ Remarks by PCS
1.	Secretarial Standards: The compliances of the listed entity are in accordance with the applicable Secretarial Standards (SS) issued by the Institute of Company Secretaries India (ICSI), as notified by the Central Government under section 118(10) of the Companies Act, 2013 and mandatorily applicable.	Yes	-
2.	Adoption and timely updation of the Policies: <ul style="list-style-type: none"> All applicable policies under SEBI Regulations are adopted with the approval of board of directors of the listed entities All the policies are in conformity with SEBI Regulations and has been reviewed & timely updated as per the regulations/circulars/ guidelines issued by SEBI 	Yes	-
3.	Maintenance and disclosures on Website: <ul style="list-style-type: none"> The Listed entity is maintaining a functional website Timely dissemination of the documents/ information under a separate section on the website Web-links provided in annual corporate governance reports under Regulation 27(2) are accurate and specific which re-directs to the relevant document(s)/ section of the website 	Yes	-
4.	Disqualification of Director: None of the Director of the Company are disqualified under Section 164 of Companies Act, 2013	Yes	-
5.	Details related to Subsidiaries of listed entities have been examined w.r.t.: (a) Identification of material subsidiary companies (b) Disclosure requirement of material as well as other subsidiaries	Yes	-
6.	Preservation of Documents: The listed entity is preserving and maintaining records as prescribed under SEBI Regulations and disposal of records as per Policy of Preservation of Documents and Archival policy prescribed under SEBI LODR Regulations, 2015.	Yes	-
7.	Performance Evaluation: The listed entity has conducted performance evaluation of the Board, Independent Directors and the Committees at the start of every financial year as prescribed in SEBI Regulations	Yes	-
8.	Related Party Transactions: (a) The listed entity has obtained prior approval of Audit Committee for all related party transactions; or (b) The listed entity has provided detailed reasons along with confirmation whether the transactions were subsequently approved/ ratified/ rejected by the Audit Committee, in case no prior approval has been obtained.	Yes	-



Sr. No.	Particulars	Compliance status (Yes/No/NA)	Observations/Remarks by PCS
9.	Disclosure of events or information: The listed entity has provided all the required disclosure (s) under Regulation 30 along with Schedule III of SEBI LODR Regulations, 2015 within the time limits prescribed thereunder.	Yes	-
10.	Prohibition of Insider Trading: The listed entity is in compliance with Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015.	Yes	-
11.	Actions taken by SEBI or Stock Exchange (s), if any: No Actions taken against the listed entity/ its promoters/ directors/ subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under SEBI Regulations and circulars/ guidelines issued thereunder.	Yes	-
12.	Resignation of statutory auditors from the listed entity or its material subsidiaries: In case of resignation of statutory auditor from the listed entity or any of its material subsidiaries during the financial year, the listed entity and / or its material subsidiary (ies) has / have complied with paragraph 6.1 and 6.2 of Section V-D of chapter V of the Master Circular on compliance with the provisions of the LODR Regulations by listed entities	N.A.	-
13.	Additional Non-compliances, if any: No additional non-compliance observed for all SEBI regulation/circular/guidance note etc.	Yes	-

We further, report that the listed entity is in compliance with the disclosure requirements of Employee Benefit Scheme Documents in terms of regulation 46(2)(za) of the LODR Regulations read with the SEBI Circular for implementation of recommendations of the Expert Committee for facilitating ease of doing business for listed entities dated December 31, 2024.

Assumptions & Limitation of scope and Review:

1. Compliance of the applicable laws and ensuring the authenticity of documents and information furnished, are the responsibilities of the management of the listed entity.
2. Our responsibility is to report based upon our examination of relevant documents and information. This is neither an audit nor an expression of opinion.
3. We have not verified the correctness and appropriateness of financial Records and Books of Accounts of the listed entity.
4. This Report is solely for the intended purpose of compliance in terms of Regulation 24A(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is neither an assurance as to the future viability of the listed entity nor of the efficacy or effectiveness with which the management has conducted the affairs of the listed entity.

For RPR & ASSOCIATES
Company Secretaries

Y Ravi Prasada Reddy
Proprietor

FCS No: 5783, C P No: 5360
Peer Review Certificate No. 1425/2021
UDIN: F005783H000244439

Place: Hyderabad
Date: April 30, 2026

Annexure – C
to the Report on Corporate Governance

To
The Audit Committee &
The Board of Directors
Laurus Labs Limited

Sub: Certificate under Regulation 17(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We, Dr. Satyanarayana Chava, Executive Director and Chief Executive Officer and Mr. V V Ravi Kumar, Executive Director and Chief Financial Officer, hereby certify as under:

- A. We have reviewed financial statements and the cash flow statement for the year ended March 31, 2026 and that to the best of our knowledge and belief:
 - (1) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (2) These statements together present a true and fair view of the Company's affairs and are in compliance with existing Accounting Standards, applicable laws and regulations.
- B. To the best of our knowledge and belief, no transactions entered into by the Company during the year ended March 31, 2026 are fraudulent, illegal or violative of the Company's Code of Conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. Deficiencies in the design or operation of such internal controls, if any, of which we are aware have been disclosed to the auditors and the Audit Committee and steps have been taken to rectify these deficiencies.
- D. We have disclosed, wherever applicable, to the auditors and the Audit Committee:
 - (1) That there have not been any significant changes in internal control over financial reporting during the year;
 - (2) That there have not been any significant changes in accounting policies during the year requiring disclosure in the notes to the financial statements; and
 - (3) That we are not aware of any instances during the year of significant fraud with involvement therein of the management or an employee having a significant role in the Company's internal control system over financial reporting.

Date: April 29, 2026
Place: Hyderabad

Sd/-
Dr. Satyanarayana Chava
Executive Director and
Chief Executive Officer
Laurus Labs Limited

Sd/-
V V Ravi Kumar
Executive Director and
Chief Financial Officer
Laurus Labs Limited

Annexure – D

to the Report on Corporate Governance

Certificate on Corporate Governance

To
The Members,
M/s. LAURUS LABS LIMITED
Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anaparthi District, Andhra Pradesh – 531021.

We have examined the compliance conditions of Corporate Governance by M/s. **Laurus Labs Limited** for the financial year ended 31st March, 2026, as stipulated in the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI (LODR) Regulations, 2015”] and the Uniform Listing Agreement entered between the Company & Stock Exchanges.

The compliance of conditions of Corporate Governance is the responsibility of the Company’s management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our knowledge and according to the explanations given to us, we certify that the Company has complied with the conditions of applicable Corporate Governance as stipulated in the above mentioned SEBI (LODR) Regulations, 2015 and the Uniform Listing Agreement.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For RPR & ASSOCIATES
Company Secretaries

Y Ravi Prasada Reddy
Proprietor

FCS No: 5783, C P No: 5360
Peer Review Certificate No. 1425/2021
UDIN: F005783H000244516

Place: Hyderabad
Date: April 30, 2026